Eduardo Chang
Pulmonary Disease · The Woodlands, TXNPI 1689683153
Payments from drug & device makers
Across 62 payments — averaging $3765.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$110K
- Astrazeneca UK Limited$67K
- AstraZeneca$54K
- Boehringer Ingelheim$2K
- Actelion Pharmaceuticals US, Inc.$143
- GSK$113
- plus $418 from 13 others
What the payments were for
- Speaking & faculty fees$1,73567%
- Food & beverage$83932%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 14 | $109,570 |
| Astrazeneca UK Limited | 2 | $67,018 |
| AstraZeneca | 4 | $54,347 |
| Boehringer Ingelheim | 8 | $1,857 |
| Actelion Pharmaceuticals US, Inc. | 6 | $143 |
| GSK | 6 | $113 |
| Vapotherm Inc | 1 | $110 |
| Sunovion Pharmaceuticals Inc. | 6 | $45 |
| Merck | 3 | $44 |
| Sanofi | 2 | $33 |
| Jazz Pharmaceuticals Inc. | 2 | $33 |
| Insmed, Inc. | 1 | $22 |
| Bayer | 1 | $22 |
| Grifols USA, LLC | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| Electromed, Inc. | 1 | $20 |
| Gilead | 1 | $19 |
| Mylan Specialty L.p. | 1 | $16 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VAPOTHERM$110
How this compares
$233,467 in reported general payments places this provider in the 90th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in The Woodlands
- Ather SiddiqiThe Woodlands$1.4M
- Jefy MathewThe Woodlands$318K
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.